Physician profile
Sameena J Rao
NPI 1649258856
$3,186.28
in general payments reported to CMS, 2019-2025
29 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $160 · 2021: $113 · 2022: $335 · 2023: $997 · 2024: $563 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860 · Travel and Lodging: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,860.34 |
| Travel and Lodging | $346.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,170.31 | 2022-2024 | Axonics, Bulkamid |
| Sumitomo Pharma America, INC. | $412.49 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $277.44 | 2022-2025 | Altaviva, Interstim |
| Medtronic USA, INC. | $132.62 | 2019-2020 | |
| Caldera Medical, INC | $112.68 | 2021 | |
| Rochester Medical Corporation | $94.39 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.91 | 2024-2025 | |
| Blue Earth Diagnostics | $81.57 | 2019 | |
| Merck Sharp & Dohme LLC | $80.68 | 2024-2025 | Lynparza, Keytruda |
| Accord Healthcare, INC. | $72.69 | 2025 | |
| Dendreon Pharmaceuticals LLC | $64.47 | 2024 | Provenge |
| Astellas Pharma US INC | $61.17 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $60.15 | 2020-2024 | Urgent Pc Neuromodulation System |
| Abbvie INC. | $55.86 | 2025 | |
| Boston Scientific Corporation | $42.44 | 2019-2025 | Axonics |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $42.26 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $41.15 | 2019 | |
| Urovant Sciences INC | $38.01 | 2022 | |
| Myovant Sciences INC. | $33.82 | 2022 | |
| Coloplast Corp | $33.18 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $28.60 | 2019 | |
| Allergan, INC. | $25.93 | 2019 | |
| Hologic Sales and Service, LLC | $25.49 | 2019 | |
| Travere Therapeutics, INC. | $22.43 | 2020 | |
| Janssen Biotech, INC. | $21.34 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $18.46 | 2025 | Lynparza |
| Alexion Pharmaceuticals, INC. | $15.57 | 2020 | |
| Antares Pharma, INC. | $14.35 | 2022 | |
| Pfizer INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameena Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.